<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58841">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340000</url>
  </required_header>
  <id_info>
    <org_study_id>3968</org_study_id>
    <nct_id>NCT02340000</nct_id>
  </id_info>
  <brief_title>Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate</brief_title>
  <official_title>Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to determine if high-dose amoxicillin/clavulanate is more effective than
      standard-dose amoxicillin/clavulanate in treating acute bacterial sinusitis in adults seen
      at a primary care office.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>subjective improvement - day 3 (rating of &quot;a lot better&quot; or &quot;no symptoms&quot;)</measure>
    <time_frame>end of 3 days of treatment</time_frame>
    <description>rating of &quot;a lot better&quot; or &quot;no symptoms&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNOT-16 - day 3</measure>
    <time_frame>end of 3 days of treatment</time_frame>
    <description>mean improvement of 0.5 or greater on each of the 16 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective improvement - day 10 (rating of &quot;a lot better&quot; or &quot;no symptoms&quot;)</measure>
    <time_frame>end of 10th day</time_frame>
    <description>rating of &quot;a lot better&quot; or &quot;no symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNOT-16 - day 10</measure>
    <time_frame>end of 10th day</time_frame>
    <description>mean improvement of 0.5 or greater on each of the 16 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects - day 3 (proportions with diarrhea, rash, vaginal candidiasis, or other side effect)</measure>
    <time_frame>end of 3 days of treatment</time_frame>
    <description>proportions with diarrhea, rash, vaginal candidiasis, or other side effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects - day 10 (proportions with diarrhea, rash, vaginal candidiasis, or other side effect)</measure>
    <time_frame>end of 10th day</time_frame>
    <description>proportions with diarrhea, rash, vaginal candidiasis, or other side effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nasal colonization with resistant bacteria</measure>
    <time_frame>at the end of the study, i.e. 2 years from start of study (or whenever 300 participants have been enrolled) (results of cultures not available to investigators until end of trial)</time_frame>
    <description>identification of participants with nasal carriage of pathogens resistant to study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>success of participant blinding (success of participants in guessing which treatment they received)</measure>
    <time_frame>end of 10th day</time_frame>
    <description>success of participants in guessing which treatment they received</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sinusitis</condition>
  <arm_group>
    <arm_group_label>standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard dose amoxicillin/clavulanate</intervention_name>
    <description>amoxicillin/clavulanate 875/125 + placebo bid x 7 days</description>
    <arm_group_label>standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose amoxicillin/clavulanate</intervention_name>
    <description>amoxicillin/clavulanate 1000/62.5 two tablets (different manufacturers) bid x 7 days</description>
    <arm_group_label>high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult 18 or over

          2. Meets definition of acute sinusitis by Infectious Disease Society of America (2012)

          3. Clinician and participant chose to start antibiotic treatment

        Exclusion Criteria:

          1. Previously enrolled in the study

          2. Allergic or intolerant to amoxicillin, penicillin, or amoxicillin/clavulanate

          3. Specific medication concerns: lactating (since safety of clavulanate unknown); taking
             allopurinol (increased risk of rash); concurrent mononucleosis (increased risk of
             rash with amoxicillin); chronic kidney disease with glomerular filtration rate &lt; 30;
             significant hepatic impairment; history of antibiotic-associated colitis

          4. Cognitive impairment so that unable to give informed consent or give reliable
             assessment of improvement

          5. Need to use high-dose amoxicillin/clavulanate: treatment with amoxicllin or
             penicillin within the past month (risk of penicillin-resistant pneumococci), very ill
             patient (though not ill enough to send to hospital); immunocompromise

          6. Need to hospitalize the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Albany Medical Center Internal Medicine and Pediatrics</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Sorum, MD</last_name>
      <phone>518-262-7500</phone>
      <email>sorump@mail.amc.edu</email>
    </contact>
    <contact_backup>
      <last_name>David Bounds</last_name>
      <phone>518-262-7500</phone>
      <email>boundsd@mail.amc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Sorum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gina Garrison, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Mulqueen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Matho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miyuki Tanino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aaron Quidort, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sujata Kane, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine McGovern, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 17, 2016</lastchanged_date>
  <firstreceived_date>November 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albany Medical College</investigator_affiliation>
    <investigator_full_name>Paul Sorum, MD</investigator_full_name>
    <investigator_title>Professor of Internal Medicine and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>acute sinusitis</keyword>
  <keyword>amoxicillin/clavulanate</keyword>
  <keyword>adults</keyword>
  <keyword>outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
